VaxGen shutters program, axes staff in second retrenchment

Troubled VaxGen has taken the axe to its budget for the second time in five months, chopping out a quarter of its workforce - 20 people - following the cancellation of a government contract for its anthrax vaccine. VaxGen is also halting any further development work on its recombinant anthrax vaccine and is actively searching for a partner. The South San Francisco-based developer handed pink slips to more than half of its staff at the beginning of the year after the company lost the federal contract for 75 million doses of vaccine.

- here's the report on VaxGen from the Charlotte Business Journal

Related story:
VaxGen misses federal deadline on anthrax vaccine. Report
US cancels VaxGen's $877M vaccine contract. Report

Suggested Articles

J&J's EGFR-fighting combo stopped tumor growth in 60% of patients whose lung cancer got worse after taking AstraZeneca's Tagrisso.

Amgen's KRAS inhibitor curbed tumor growth in 88% of patients with non-small cell lung cancer, shrinking tumors in one-third of them.

The trial squeezed under the bar for statistical significance by improving on the median progression-free survival of Zytiga by two months.